Wolters Kluwer, Health, a global provider of trusted clinical technology and evidence-based solutions, has announced the integration of DoseMeRx™, a Tabula Rasa Healthcare precision dosing solution, with Sentri7’s Antimicrobial Stewardship (AMS) solution. With a single click, pharmacists can review patient-specific parenteral vancomycin dose recommendations calculated automatically using key clinical data such as patient weight, laboratory values, creatinine levels and drug administration times.
“Dosing and monitoring of vancomycin can be complex, requiring patient data and laboratory results to individualize the dose for each patient,” said Charles Cornish, Executive Vice President, Hospitals Business Unit, TRHC. “By integrating our precision dosing platform with Wolters Kluwer’s Sentri7 solution, pharmacists across the country will have convenient, integrated real-time Bayesian dosing support to align with the best practices in the American Society of Health System Pharmacists 2020 guideline recommendation for dosing and monitoring of vancomycin.”
Vancomycin is one of the most commonly used antibiotics in hospitals today. Traditionally, calculating vancomycin doses for patients requires coordination among pharmacists, nurses, and laboratory technicians, as well as manual calculations that are time-consuming. With the DoseMeRx integration, pharmacists have automated access to faster, more precise calculations, without any data entry, and proactively monitor for adjustments to reduce a patient’s risk of acute kidney injury.
“Pharmacists are routinely challenged by how best to avoid adverse drug events in patients. By improving the methodology for precision dosing, pharmacists can focus on delivering the best possible patient care,” said Karen Kobelski, Vice President and General Manager, Clinical Surveillance, Compliance & Data Solutions at Wolters Kluwer, Health. “With the seamless transfer of patient specific parameters between Sentri7 and DoseMeRx, clinical teams have the expert solutions they need to predict more accurate drug concentration over time.”
In addition to the DoseMeRx real-time vancomycin dosing platform, pharmacists can leverage Sentri7’s evidence-based AMS rules to assess appropriate vancomycin use and keep prescribing in line with their hospital’s antimicrobial stewardship goals and the CDC’s Core Elements of Antimicrobial Stewardship program.
See the original press release here.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
DoseMeRx is a Tabula Rasa HealthCare technology solution (NASDAQ: TRHC) developed specifically for clinical practice. The DoseMeRx clinical decision support solution empowers healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs and improve patient outcomes. For more information, visit doseme-rx.com
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) provides medication safety solutions that empower healthcare professionals to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events. TRHC’s technology solutions, including DoseMeRx™ and MedWise™, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC’s extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and pharmacies to help drive value-based payment results. For more information, visit TRHC.com.